PATUSKY CHRISTOPHER 4

What Happened

• Christopher Patusky, a director of United Therapeutics (UTHR), received 650 shares of common stock on July 9, 2026 when restricted stock units (RSUs) vested and were converted one-for-one into shares. The transaction shows an acquisition of 650 shares at $0.00 and a corresponding disposition of 650 derivative units at $0.00 — the disposition reflects the conversion of the RSU (derivative) into common stock, not a sale of shares.

Key Details

• Transaction date: July 9, 2026; Form 4 filed July 13, 2026 (filed within the required two business days).
• Price: $0.00 per share; total reported value $0.
• Shares received: 650 common shares via RSU vesting/conversion.
• Shares owned after the transaction: not specified in the information provided.
• Footnotes: F1 — RSUs converted one-for-one into shares upon vesting on July 9, 2026. F2 — Not applicable; RSUs do not have an expiration date.
• Transaction codes: M (exercise or conversion of a derivative security). This filing reports conversion of RSUs, not an open-market purchase or sale.

Context

• This is an award/vesting event (routine compensation/long-term incentive) rather than a market purchase or sale. Such conversions are common for executives/directors receiving equity compensation and do not by themselves indicate buying or selling sentiment.